MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Price, Quote, News and Overview
NASDAQ:MDGL - Nasdaq - US5588681057 - Common Stock - Currency: USD
MDGL Quote, Performance and Key Statistics
336.23
-14.8 (-4.22%)
The current stock price of MDGL is 336.23 USD. In the past month the price decreased by -1.15%. In the past year, price increased by 42.15%.
MDGL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About MDGL
Company Profile
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 376 full-time employees. The company went IPO on 2007-02-06. The firm is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The firm's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Company Info
MADRIGAL PHARMACEUTICALS INC
200 Barr Harbor Dr Ste 400
West Conshohocken PENNSYLVANIA 19428 US
CEO: Paul A. Friedman
Employees: 376
Company Website: https://www.madrigalpharma.com/
Investor Relations: https://ir.madrigalpharma.com/
Phone: 14043809263
MADRIGAL PHARMACEUTICALS INC / MDGL FAQ
What is the stock price of MADRIGAL PHARMACEUTICALS INC today?
The current stock price of MDGL is 336.23 USD. The price decreased by -4.22% in the last trading session.
What is the ticker symbol for MADRIGAL PHARMACEUTICALS INC stock?
The exchange symbol of MADRIGAL PHARMACEUTICALS INC is MDGL and it is listed on the Nasdaq exchange.
On which exchange is MDGL stock listed?
MDGL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MADRIGAL PHARMACEUTICALS INC stock?
22 analysts have analysed MDGL and the average price target is 388.42 USD. This implies a price increase of 15.52% is expected in the next year compared to the current price of 336.23. Check the MADRIGAL PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MADRIGAL PHARMACEUTICALS INC worth?
MADRIGAL PHARMACEUTICALS INC (MDGL) has a market capitalization of 7.33B USD. This makes MDGL a Mid Cap stock.
How many employees does MADRIGAL PHARMACEUTICALS INC have?
MADRIGAL PHARMACEUTICALS INC (MDGL) currently has 376 employees.
What are the support and resistance levels for MADRIGAL PHARMACEUTICALS INC (MDGL) stock?
MADRIGAL PHARMACEUTICALS INC (MDGL) has a support level at 336.22 and a resistance level at 350.71. Check the full technical report for a detailed analysis of MDGL support and resistance levels.
Should I buy MADRIGAL PHARMACEUTICALS INC (MDGL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MDGL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MDGL, evaluating the profitability, health, valuation and growth aspects
- MADRIGAL PHARMACEUTICALS INC (MDGL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MADRIGAL PHARMACEUTICALS INC (MDGL) Sales and EPS estimates to see what analysts future expectations are.
- MADRIGAL PHARMACEUTICALS INC (MDGL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MADRIGAL PHARMACEUTICALS INC (MDGL) Insider and Institutional Ownership to learn about the owners and their transactions.
- MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Chart to make your own analysis
- MADRIGAL PHARMACEUTICALS INC (MDGL) Latest news and press-releases to stay up to date.
Does MADRIGAL PHARMACEUTICALS INC (MDGL) stock pay dividends?
MDGL does not pay a dividend.
When does MADRIGAL PHARMACEUTICALS INC (MDGL) report earnings?
MADRIGAL PHARMACEUTICALS INC (MDGL) will report earnings on 2025-02-26, before the market open.
What is the Price/Earnings (PE) ratio of MADRIGAL PHARMACEUTICALS INC (MDGL)?
MADRIGAL PHARMACEUTICALS INC (MDGL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-25.08).
What is the Short Interest ratio of MADRIGAL PHARMACEUTICALS INC (MDGL) stock?
The outstanding short interest for MADRIGAL PHARMACEUTICALS INC (MDGL) is 20% of its float. Check the ownership tab for more information on the MDGL short interest.
MDGL Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to MDGL. When comparing the yearly performance of all stocks, MDGL is one of the better performing stocks in the market, outperforming 85.51% of all stocks.
MDGL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MDGL. The financial health of MDGL is average, but there are quite some concerns on its profitability.
MDGL Financial Highlights
Over the last trailing twelve months MDGL reported a non-GAAP Earnings per Share(EPS) of -25.08. The EPS decreased by -30.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.92% | ||
| ROE | -60.97% | ||
| Debt/Equity | 0.14 |
MDGL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to MDGL. The Buy consensus is the average rating of analysts ratings from 22 analysts.